Abstract 54P
Background
Surgery is performed after neoadjuvant chemoradiotherapy (CRT) as standard in locally advanced rectal cancer. However, in recent years, it has been observed that oncological outcomes can be improved with a treatment approach called total neoadjuvant therapy (TNT), applied with different strategies. This meta-analysis investigated the efficacy of randomized controlled trials (RCTs) comparing standard CRT with TNT.
Methods
PubMed and Cochrane Library databases were searched for this meta-analysis, and studies published until 01 January 2022 were included in the analysis. Standard arm; Patients who underwent surgery after neoadjuvant CRT, and the TNT arm was defined as patients who received chemotherapy for at least 3 months before or after CRT or short-term RT, and then surgery. This Meta-analysis was performed using Review Manager, version 5.4 (RevMan), a proprietary software provided by the Cochrane Collaboration.
Results
Six RCTs were included in this meta-analysis, and a total of 2307 patients were analyzed (three phase 3, three phase 2). There were 1195 patients in the TNT arm and 1112 patients in the CRT arm, with a median age of 62 years in both arms. In the joint analysis of the six studies, the pathological complete response rate was 25% in the TNT arm and 13% in the CRT arm (OR:2.13, 95% CI 1.71-2.65, p<0.001)(I2 =47% ). There are 3 studies reporting 3-year disease-free survival results, and in the joint analysis of these studies, 3-year disease-free survival rate was 74.2% in the TNT arm, while it was 69% in the CRT arm (HR :1.31, 95% CI 1.07-1.60, p=0.01)( I2= 0%). Because overall survival data were not shared in most studies, overall survival analysis could not be performed.
Conclusions
In locally advanced rectal cancer, the rate of pathological complete response with TNT increases 2 times compared to standard CRT. In addition, 3-year disease-free survival results were found to be better with TNT. Longer follow-up results need to be awaited to see if the better pathological complete response and 3-year disease-free survival achieved with TNT are reflected in overall survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02